IL-33 drives the antitumour effects of dendritic cells via upregulating CYLD expression in pulmonary adenocarcinoma

References:

• Yong KJ, Basseres DS, Welner RS, et al. Targeted BMI1 inhibition impairs tumour growth in lung adenocarcinomas with low CEBPα expression. Sci Transl Med. 2016;8:350ra104.
   PubMed Web of Science ®Google Scholar
• Caronni N, Simoncello F, Stafetta F, et al. Downregulation of membrane trafficking proteins and lactate conditioning determine loss of dendritic cell function in lung cancer. Cancer Res. 2018;78:1685–1699.
   PubMed Web of Science ®Google Scholar
• Eissmann MF, Dijkstra C, Wouters MA, et al. Interleukin 33 signaling restrains sporadic colon cancer in an interferon-gamma-dependent manner. Cancer Immunol Res. 2018;6:409–421.
   PubMed Web of Science ®Google Scholar
• Lopetuso LR, De Salvo C, Pastorelli L, et al. Il-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. Proc Natl Acad Sci USA. 2018;115:E9362–e9370.
   PubMed Web of Science ®Google Scholar
• Staurengo-Ferrari L, Trevelin SC, Fattori V, et al. Interleukin-33 receptor (st2) deficiency improves the outcome of Staphylococcus aureus-induced septic arthritis. Front in Immunol. 2018;9:962.
   PubMed Web of Science ®Google Scholar
• Takatori H, Makita S, Ito T, et al. Regulatory mechanisms of IL-33-ST2-mediated allergic inflammation. Front in Immunol. 2018;9:2004.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Cui X, Li W, et al. BLT1 signaling in epithelial cells mediates allergic sensitization via promotion of IL-33 production. Allergy 2019;74:495–506.
   PubMed Web of Science ®Google Scholar
• Xiao P, Wan X, Cui B, et al. Interleukin 33 in tumour microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells. Oncoimmunology 2016;5:e1063772.
   PubMed Web of Science ®Google Scholar
• Fang M, Li Y, Huang K, et al. IL33 promotes colon cancer cell stemness via jnk activation and macrophage recruitment. Cancer Res. 2017;77:2735–2745.
   PubMed Web of Science ®Google Scholar
• Gao K, Li X, Zhang L, et al. Transgenic expression of IL-33 activates CD8+ T cells and NK cells and inhibits tumour growth and metastasis in mice. Cancer Lett. 2013;335:463–471.
   PubMed Web of Science ®Google Scholar
• Gao X, Wang X, Yang Q, et al. Tumoural expression of IL-33 inhibits tumour growth and modifies the tumour microenvironment through CD8+ T and NK cells. JI. 2015;194:438–445.
   Google Scholar
• Kim J, Kim W, Moon UJ, et al. Intratumourally establishing type 2 innate lymphoid cells blocks tumour growth. JI. 2016;196:2410–2423.
   Google Scholar
• Lucarini V, Ziccheddu G, Macchia I, et al. IL-33 restricts tumour growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. Oncoimmunology 2017;6:e1317420.
   PubMed Web of Science ®Google Scholar
• Dominguez D, Ye C, Geng Z, et al. Exogenous IL-33 restores dendritic cell activation and maturation in established cancer. J Immunol. 2017;198:1365–1375.
   PubMed Web of Science ®Google Scholar
• Hsu YL, Hung JY, Lee YL, et al. Identification of novel gene expression signature in lung adenocarcinoma by using next-generation sequencing data and bioinformatics analysis. Oncotarget 2017;8:104831–104854.
   PubMedGoogle Scholar
• Yang M, Feng Y, Yue C, et al. Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. PLoS One. 2018;13:e0193428.
   PubMed Web of Science ®Google Scholar
• Jang JS, Lee JH, Jung NC, et al. Rsad2 is necessary for mouse dendritic cell maturation via the IRF7-mediated signaling pathway. Cell Death Dis. 2018;9:823.
   PubMed Web of Science ®Google Scholar
• Li R, Fang F, Jiang M, et al. STAT3 and NF-κB are simultaneously suppressed in dendritic cells in lung cancer. Sci Rep. 2017;7:45395.
   PubMed Web of Science ®Google Scholar
• Bergeron A, El-Hage F, Kambouchner M, et al. Characterisation of dendritic cell subsets in lung cancer micro-environments. The Euro Resp J. 2006;28:1170–1177.
   PubMed Web of Science ®Google Scholar
• Liu N, Jiang Y, Chen J, et al. IL-33 drives the antitumour effects of dendritic cells via the induction of TC9 cells. Cell Mol Immunol. 2018. https://www.nature.com/articles/s41423-018-0166-0
   Web of Science ®Google Scholar
• Carmi Y, Spitzer MH, Linde IL, et al. Allogeneic igg combined with dendritic cell stimuli induce antitumour t-cell immunity. Nature 2015;521:99–104.
   PubMed Web of Science ®Google Scholar
• Gurusamy D, Clever D, Eil R, et al. Novel “elements” of immune suppression within the tumour microenvironment. Cancer Immunol Res. 2017;5:426–433.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumour microenvironment. Nat Immunol. 2013;14:1014–1022.
   PubMed Web of Science ®Google Scholar
• Su S, Liao J, Liu J, et al. Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer. Cell Res. 2017;27:461–482.
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in tumour immunity. Int J Cancer. 2010;127:759–767.
   PubMed Web of Science ®Google Scholar
• Zhou J, Li X, Wu X, et al. Exosomes released from tumour-associated macrophages transfer miRNAs that induce a treg/th17 cell imbalance in epithelial ovarian cancer. Cancer Immunol Res. 2018;6:1578–1592.
   PubMed Web of Science ®Google Scholar
• Tran Janco JM, Lamichhane P, Karyampudi L, et al. Tumour-infiltrating dendritic cells in cancer pathogenesis. JI. 2015;194:2985–2991.
   Google Scholar
• Zhang Y, Hu X, Hu Y, et al. Anti-CD40-induced inflammatory E-cadherin + dendritic cells enhance T cell responses and antitumour immunity in murine Lewis lung carcinoma. J Exp Clin Cancer Res. 2015;34:11.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhao Y, Jiang Y, et al. Interleukin-33 contributes to the induction of th9 cells and antitumour efficacy by dectin-1-activated dendritic cells. Front Immunol. 2018;9:1787.
   PubMed Web of Science ®Google Scholar
• Garzon-Muvdi T, Theodros D, Luksik AS, et al. Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma. Oncotarget 2018;9:20681–20697.
   PubMedGoogle Scholar
• Spranger S, Dai D, Horton B, et al. Tumour-residing batf3 dendritic cells are required for effector t cell trafficking and adoptive t cell therapy. Cancer Cell. 2017;31:711–723.
   PubMed Web of Science ®Google Scholar
• Arae K, Morita H, Unno H, et al. Chitin promotes antigen-specific th2 cell-mediated murine asthma through induction of IL-33-mediated IL-1β production by DCs. Sci Rep. 2018;8:11721.
   PubMed Web of Science ®Google Scholar
• Park SH, Kim MS, Lim HX, et al. IL-33-matured dendritic cells promote th17 cell responses via IL-1β and IL-6. Cytokine 2017;99:106–113.
   PubMed Web of Science ®Google Scholar
• Alameda JP, Fernandez-Acenero MJ, Moreno-Maldonado R, et al. CYLD regulates keratinocyte differentiation and skin cancer progression in humans. Cell Death & Disease 2011;2:e208.
   PubMed Web of Science ®Google Scholar
• Hellerbrand C, Bumes E, Bataille F, et al. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 2007;28:21–27.
   PubMed Web of Science ®Google Scholar
• Liu P, Xu B, Shen W, et al. Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia 2012;26:1293–1300.
   PubMed Web of Science ®Google Scholar
• Yang Y, Ran J, Sun L, et al. CYLD regulates noscapine activity in acute lymphoblastic leukemia via a microtubule-dependent mechanism. Theranostics 2015;5:656–666.
   PubMed Web of Science ®Google Scholar
• Pannem RR, Dorn C, Ahlqvist K, et al. CYLD controls c-myc expression through the jnk-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis 2014;35:461–468.
   PubMed Web of Science ®Google Scholar
• Tang Y, Reissig S, Glasmacher E, et al. Alternative splice forms of CYLD mediate ubiquitination of SMAD7 to prevent TGFB signaling and promote colitis. Gastroenterology 2019;156:692–707.
   PubMed Web of Science ®Google Scholar
• Lim JH, Stirling B, Derry J, et al. Tumour suppressor CYLD regulates acute lung injury in lethal streptococcus pneumoniae infections. Immunity 2007;27:349–360.
   PubMed Web of Science ®Google Scholar
• Wex K, Schmid U, Just S, et al. Receptor-interacting protein kinase-2 inhibition by CYLD impairs antibacterial immune responses in macrophages. Front in Immunol. 2015;6:650.
   PubMed Web of Science ®Google Scholar
• Legarda D, Justus SJ, Ang RL, et al. CYLD proteolysis protects macrophages from TNF-mediated auto-necroptosis induced by LPS and licensed by type I IFN. Cell Reports. 2016;15:2449–2461.
   PubMed Web of Science ®Google Scholar
• Srokowski CC, Masri J, Hovelmeyer N, et al. Naturally occurring short splice variant of CYLD positively regulates dendritic cell function. Blood 2009;113:5891–5895.
   PubMed Web of Science ®Google Scholar